AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 vTv TherapeuticsTyme TechnologiesParatek PharmaceuticalsHelix BiopharmaNewron Pharmaceuticals
SymbolNASDAQ:VTVTNASDAQ:TYMENASDAQ:PRTKOTCMKTS:HBPCFOTCMKTS:NWPHF
Price Information
Current Price$2.88$1.54$4.44$0.89$8.90
52 Week RangeBuyBuyBuyN/AN/A
Beat the Market™ Rank
Overall Score1.81.31.50.50.6
Analysis Score3.53.53.50.00.0
Community Score2.62.42.62.32.2
Dividend Score0.00.00.00.00.0
Ownership Score3.00.01.00.00.0
Earnings & Valuation Score0.00.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyN/AN/A
Consensus Price Target$7.00$9.50$18.50N/AN/A
% Upside from Price Target143.06% upside516.88% upside316.67% upsideN/AN/A
Trade Information
Market Cap$191.79 million$195.32 million$189.78 million$118.31 million$158.87 million
Beta-1.991.011.52-0.030.07
Average Volume637,151472,183799,1361981,600
Sales & Book Value
Annual Revenue$2.76 millionN/A$16.54 millionN/A$7.88 million
Price / Sales70.72N/A11.58N/A20.16
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.91) per share$0.09 per share($1.28) per share($0.02) per share$2.31 per share
Price / Book-3.16N/A-3.47N/A3.85
Profitability
Net Income$-13,040,000.00$-22,000,000.00$-128,790,000.00$-5,680,000.00$-22,630,000.00
EPS($0.37)($0.17)($3.93)N/A($1.27)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/A11.41
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-870.88%N/A-528.28%N/AN/A
Return on Equity (ROE)N/A-289.34%-5,327.73%N/AN/A
Return on Assets (ROA)-150.44%-117.47%-47.65%-447.54%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.46%
Current Ratio0.29%2.32%5.27%1.53%10.72%
Quick Ratio0.29%2.32%4.95%1.53%10.71%
Ownership Information
Institutional Ownership Percentage8.23%11.83%43.37%N/AN/A
Insider Ownership Percentage1.50%27.17%7.70%7.60%N/A
Miscellaneous
Employees52111012224
Shares Outstanding67.77 million122.84 million43.13 million132.93 million17.85 million
Next Earnings Date7/29/2020 (Estimated)8/13/2020 (Estimated)8/4/2020 (Estimated)6/9/2020 (Estimated)6/4/2020 (Estimated)
OptionableNot OptionableOptionableOptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.